Benowitz, Andrew B.

The PROTACtable genome

Schneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery

Protein Degradation and InhibitorsComputational Drug Discovery Methods

Cited by 273

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

Mares, A., Miah, A. H., Smith, I. E. D., Rackham, M., Thawani, A. R., Cryan, J., Haile, P. A., Votta, B. J., Beal, A. M., Capriotti, C., et al. (2020) · Communications Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 232

Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs

Anderson, N. A., Cryan, J., Ahmed, A., Dai, H., McGonagle, G. A., Rozier, C., & Benowitz, A. B. (2020) · Bioorganic & Medicinal Chemistry Letters

Protein Degradation and InhibitorsAdvanced Breast Cancer Therapies

Cited by 69

Identification of an allosteric site on the E3 ligase adapter cereblon

Dippon, V. N., Rizvi, Z., Choudhry, A. E., Chung, C.-W., Alkuraya, I. F., Xu, W., Tao, X. B., Jurewicz, A. J., Schneck, J. L., Chen, W., et al. (2026) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 14

Abstract 2994: Discovery of selective, noncovalent small molecule inhibitors of DNMT1 as an alternative to traditional DNA hypomethylating agents

Pappalardi, M. B., Cockerill, M., Handler, J. L., Stowell, A., Keenan, K., Sherk, C. S., Minthorn, E. A., McHugh, C. F., Burt, C., Wong, K., et al. (2018) · Cancer Research

Epigenetics and DNA MethylationHistone Deacetylase Inhibitors Research

Cited by 9